Evidence Hub

Quality by Design (QbD) Based Development and Optimization of Levocetirizine Sustained Release Oral Tablets

Dr. Priyanka Nagar Ajay Lohare *

Zenodo (CERN European Organization for Nuclear Research), 2026

Abstract

Allergic disorders such as allergic rhinitis and chronic urticaria affect a large portion of the population and often require long-term antihistamine therapy. Levocetirizine, a third-generation H1 receptor antagonist, is widely used due to its efficacy and lower sedative effects. However, conventional immediate-release formulations may lead to fluctuations in plasma drug concentration and require repeated dosing, which can reduce patient compliance and therapeutic consistency. Sustained release (SR) oral drug delivery systems offer a promising strategy to overcome these limitations by providing controlled and prolonged drug release. Such systems help maintain steady plasma levels, reduce dosing frequency, and potentially minimize side effects, thereby improving overall treatment outcomes in chronic allergic conditions. Quality by Design (QbD) has become an important approach in modern pharmaceutical development. It focuses on predefined product objectives, identification of critical quality attributes, risk assessment, and systematic optimization using design of experiments. By applying QbD principles to the development of levocetirizine sustained release tablets, a robust and reliable formulation can be achieved with consistent performance and regulatory compliance. This review highlights the need for sustained release levocetirizine formulations and discusses the application of QbD principles in their development and optimization.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free